Found: 8
Select item for more details and to access through your institution.
Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. E83, doi. 10.1002/ajh.26434
- By:
- Publication type:
- Article
Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 6, p. 708, doi. 10.1002/ajh.26172
- By:
- Publication type:
- Article
Daratumumab in transfusion‐dependent patients with low or intermediate‐1 risk myelodysplastic syndromes.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 4, p. E111, doi. 10.1002/ajh.26095
- By:
- Publication type:
- Article
OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S32, doi. 10.1016/S2152-2650(21)02124-8
- By:
- Publication type:
- Article
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41408-021-00593-2
- By:
- Publication type:
- Article
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 5, p. 1292, doi. 10.1002/cam4.4478
- By:
- Publication type:
- Article
Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma.
- Published in:
- Clinical Pharmacokinetics, 2012, v. 51, n. 12, p. 823, doi. 10.1007/s40262-012-0010-0
- By:
- Publication type:
- Article